Overview

Naltrexone Neuroimaging

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid antagonism in adolescents with ED. Modulation of brain activation will be examined in regions of interest by fMRI using a food-specific and general reward task in adolescents with ED in a pre/post design.
Phase:
Early Phase 1
Details
Lead Sponsor:
Children's Mercy Hospital Kansas City
Collaborator:
University of Kansas Medical Center
Treatments:
Naltrexone